Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02459964 · ClinicalTrials.gov registry record · Phase 4
Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain
A Phase 4 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 84
- Enrollment target
NCT02459964: Completed Phase 4 study, sponsored by M.D. Anderson Cancer Center.
NCT02459964 is a Phase 4 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 84 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02459964, a Phase 4 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 84 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to compare fentanyl nasal spray with a standard drug given by vein (hydromorphone hydrochloride) to help reduce pain related to cancer in patients coming to the emergency department.
Interventions
- DRUG Hydromorphone Hydrochloride
- BEHAVIORAL Phone Call
- DRUG Fentanyl Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2015-09-14 |
| Est. Completion | 2020-06-21 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02459964
The ClinicalTrials.gov registry entry for NCT02459964 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Hydromorphone Hydrochloride is the first listed.
NCT02459964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02459964 about?
NCT02459964 is a clinical study titled "Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain". The goal of this clinical research study is to compare fentanyl nasal spray with a standard drug given by vein (hydromorphone hydrochloride) to help reduce pain related to cancer in patients coming to the emergency department.
What is the current status of trial NCT02459964?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 84 participants. The study started on 2015-09-14. Estimated completion is 2020-06-21.
What interventions are being tested in trial NCT02459964?
The interventions under investigation include: Hydromorphone Hydrochloride (DRUG), Phone Call (BEHAVIORAL), Fentanyl Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT02459964?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.